Niva Bupa Health Insurance Company

NIVABUPA (₹75.85) presents a conflicting technical picture on November 6, 2026. While the daily trend shows price holding above short-term averages (20-period EMA and SMA), it remains firmly below longer-term resistance levels (50-period and 200-period SMAs) and the Supertrend indicator, which is bearish across daily, weekly, and monthly timeframes. The ADX of 19.9 indicates weak trend strength on the daily chart, suggesting consolidation rather than a decisive breakout.

Momentum is mixed: a +5.2% unusual upward move occurred on November 4, followed by a Bullish Engulfing Reversal pattern, yet the stock closed lower (-1.2%) on November 6. An active Inside Bar formation on the monthly timeframe suggests potential for a significant directional move, but the broader context remains cautious given the -17.9% current drawdown and 30.8% annualized volatility. Key support lies at ₹75.24 (0.80% below), with immediate resistance at ₹75.92 (0.09% above). A sustained close above ₹75.92 would be required to validate near-term bullish momentum; failure to hold above ₹75.24 could expose the stock to further downside toward ₹73.74.

Niva Bupa Health Insurance reported a 124% year-on-year surge in second-quarter profit after tax to ₹136 crore, driven by strong growth in its retail health insurance business. Gross written premiums increased 35% to ₹2,484 crore, with retail health premiums rising 47% to ₹1,876 crore. The company also noted an improved expense ratio of 36.4% for the first half, down from 37.2% in the previous year.

In a separate development, the Surat District Consumer Disputes Redressal Commission ruled that Niva Bupa cannot repudiate a claim for ovarian tumour treatment based on the non-disclosure of an unrelated wrist ailment (Kienbock disease). The commission directed the insurer to reimburse Rs 75,449 plus 7% annual interest, along with compensation for mental agony and litigation expenses, after finding no medical link between the two conditions.

While these events highlight operational strength and a specific legal precedent regarding claim repudiation, broader sector context indicates that general insurers faced underwriting losses in the September quarter due to severe monsoon flood claims and aggressive price discounting in fire insurance. However, standalone health insurers like Niva Bupa achieved profitability driven by premium growth and tax exemptions.

On November 6, 2026, Niva Bupa Health Insurance Company Limited filed its unaudited financial results for the half-year and quarter ended September 30, 2026, with the National Stock Exchange. The company’s share price was recorded at ₹75.85 on this date, reflecting a decline from the previous close of ₹76.88.

The broader insurance sector faced headwinds in the September quarter due to severe monsoon flood claims and aggressive discounting in fire insurance, which caused underwriting losses for multiline general insurers. However, standalone health insurers like Niva Bupa reported profitability, driven by premium growth and tax exemptions. While investment gains helped offset some sector-wide strain, heavy claims burdens have pressured solvency ratios for certain players.

Niva Bupa Health Insurance Company Limited’s Board approved unaudited financial results for the half-year ended September 30, 2026, on November 4, 2026. The company reported a Year-to-Date (YTD) Profit Before Tax of ₹46,246 lakhs and Gross Written Premium (GWP) of ₹858,592 lakhs. Solvency stood at 2.49 times as of March 31, 2026. Joint statutory auditors issued an unmodified review conclusion.

Regulatory compliance remains a focal point. On August 19, 2026, the Insurance Regulatory and Development Authority of India (IRDAI) warned the company for exceeding Expenses of Management (EoM) limits in FY 2024-25 and directed a six-month ban on opening new places of business. The company accepted this order without appeal. Despite this, the company reported compliance with applicable EoM limits for the quarter and YTD ended September 30, 2026. Additionally, the company received a GST refund of ₹2,213 lakhs in July 2026 after a reduction in demand from ₹2,928 lakhs to ₹287 lakhs by the Adjudicating Authority.

Governance updates include the consolidation of Unpublished Price Sensitive Information (UPSI) policies into a single document aligned with SEBI regulations, designating the Company Secretary & Compliance Officer as Chief Investor Relations Officer, and establishing an Inquiry Committee.

Niva Bupa Health Insurance Company demonstrates a divergence between top-line growth and bottom-line profitability in the latest reporting periods. Sales grew 35% year-on-year to ₹6,695 crore for the year ended March 2026, with trailing twelve-month (TTM) sales reaching ₹7,907 crore. However, net profit declined significantly from ₹214 crore in FY2025 to ₹131 crore in FY2026, resulting in a negative TTM compounded profit growth of -43%. This compression is evident in quarterly results where the company reported an operating loss of ₹53 crore and a net loss of ₹35 crore in September 2025, compared to a net profit of ₹13 crore in the prior year period.

Financial health remains robust with zero interest costs across all reported periods, indicating no reliance on debt for operations. Borrowings are stable at approximately ₹250–₹268 crore. The balance sheet shows substantial investments growing from ₹8,175 crore to ₹9,670 crore annually, while tangible fixed assets increased to ₹85 crore. Solvency ratios decreased from ₹2.85 to ₹2.03 in recent quarters, reflecting the impact of rapid asset base expansion. Return on Equity (ROE) has remained low, averaging 3-5% over three years, suggesting that current earnings levels do not yet fully capitalize the equity base.

Niva Bupa Health Insurance delivered a 124% year-on-year surge in second-quarter profit after tax to ₹136 crore, driven by robust growth in its retail health insurance segment. Gross written premiums increased 35% to ₹2,484 crore, with retail health premiums rising 47% to ₹1,876 crore. The company also reported an improved expense ratio of 36.4% for the first half, down from 37.2% in the previous year. This performance contrasts with the broader general insurance sector, which faced underwriting losses in the September quarter due to severe monsoon flood claims and aggressive price discounting in fire insurance; standalone health insurers like Niva Bupa achieved profitability despite these headwinds. While technical indicators show a bearish trend with the stock trading at ₹75.85 and a current drawdown of -17.9%, the fundamental operating metrics highlight strong underlying business momentum and margin efficiency.

Niva Bupa Health Insurance faces a mix of operational headwinds and technical deterioration. While the company reported strong Q2 profitability, with profit after tax surging 124% to ₹136 crore on 35% gross written premium growth, these gains are offset by significant external risks. The broader general insurance sector is grappling with underwriting losses from severe monsoon floods and aggressive price discounting in fire insurance, which pressures solvency ratios across the industry. On the regulatory front, Niva Bupa was directed by the Surat District Consumer Disputes Redressal Commission to reimburse ₹75,449 plus interest for an ovarian tumour claim, highlighting potential litigation risks regarding claim repudiation based on non-disclosure of unrelated ailments. Technically, the stock exhibits bearish momentum across daily, weekly, and monthly timeframes, with a current drawdown of -17.9% and a maximum drawdown of -25.9%. The share price closed at ₹75.85, trading below key moving averages, with resistance forming closely at ₹75.92.